Sensorion’s Phase I/II gene therapy trial to continue with DMC recommendation
Sensorion's Audiogene Phase I/II trial of the SENS-501 gene therapy programme has received a favourable recommendation from ...
Latus Bio Announces Data Presentations in Support of its Preclinical Huntington’s Disease Gene Therapy Program
Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data ...
pharmaphorum33m
Pfizer drops Beqvez, leaving gene therapy cupboard bare
Beqvez was Pfizer's first gene therapy, stemming from an alliance with Spark Therapeutics (now part of Roche) more than a ...
National Health Executive18m
Gene therapy breakthrough brings life-changing benefits
In a major breakthrough, four children born with severe visual impairments have experienced life-changing improvements in their ...
News Medical on MSN18m
Considerations for taking ASO discovery programs into animal models
Strong evidence for ALS often comes from familial forms of the disease, where specific gene mutations— for example in the ...
manilatimes15m
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
- Expands global ELEVATE-44 clinical program to include pediatric, adult, ambulatory and non-ambulatory patients with Duchenne muscular dystrophy - ...